Alector, Inc. — Q1 2023 Form 10-Q Summary
Business context and reporting period
For the three months ended March 31, 2023. Alector is a clinical-stage biopharmaceutical company developing immuno-neurology therapies for neurodegenerative diseases. Its lead programs are latozinemab (FTD), AL002 (Alzheimer’s disease), and AL101 (planned development in Alzheimer’s disease); it has no approved products and no product-sales revenue. Results are unaudited.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / prior period |
|---|---|---|
| Collaboration revenue | $16.5 million | $24.5 million |
| Research and development expense | $51.9 million | $53.0 million |
| General and administrative expense | $14.8 million | $15.6 million |
| Operating loss | $50.1 million | $44.1 million |
| Other income, net | $5.2 million | $0.3 million |
| Net loss | $45.9 million | $44.6 million |
| Net loss per share, basic and diluted | $0.55 | $0.54 |
| Cash used in operating activities | $48.5 million | Cash provided: $135.1 million |
At March 31, 2023, cash and cash equivalents were $195.6 million and marketable securities were $473.8 million, totaling $669.3 million. Current assets were $686.0 million versus current liabilities of $99.3 million. Total liabilities were $565.3 million, including $492.9 million of deferred collaboration revenue and lease liabilities; the balance sheet reports no borrowings. Stockholders’ equity was $183.0 million and accumulated deficit was $625.5 million. No operating margin is presented; the company reported an operating loss.
Material changes versus the prior comparable period
- Collaboration revenue declined $7.9 million, or about 32%, primarily because less GSK revenue was recognized, partly offset by AL002 long-term extension work under the AbbVie collaboration.
- R&D expense decreased $1.2 million overall: lower latozinemab and other-program costs were largely offset by increased AL002 enrollment and the LTE trial. G&A expense decreased $0.8 million.
- Net loss widened $1.2 million despite substantially higher investment income, which rose $4.9 million due to higher yields.
- Operating cash flow shifted from $135.1 million provided in Q1 2022 to $48.5 million used in Q1 2023. The prior-year period included GSK’s $200 million upfront payment. Q1 2023 investing cash flow was $88.7 million provided, mainly reflecting marketable-security maturities exceeding purchases.
Outlook, commentary, risks, and unusual items
- Management expects existing cash, cash equivalents, and investments to fund operations and capital expenditures through 2025, while cautioning that assumptions may prove inaccurate and additional financing may be needed.
- Management expected to discuss INFRONT-3 statistical analysis plans with regulators in mid-2023, targeted trial data in early 2025, and a possible BLA filing in late 2025, subject to regulatory discussions. The company expected AL002 INVOKE-2 enrollment to finish in Q3 2023 and top-line data in Q4 2024; it planned additional INFRONT-2 FTD-C9orf72 data in the second half of 2023. These are forward-looking expectations, not guarantees.
- In March 2023, Alector initiated a workforce reduction of approximately 11% (about 30 employees) to prioritize late-stage programs. It recorded $1.7 million in restructuring costs in Q1 and expected total charges of about $2.1 million, with a further $0.4 million expected before year-end.
- In February 2023, AbbVie amended its agreement and Alector received a $17.8 million milestone for the first patient dosed in the AL002 LTE trial. A further $12.5 million may be available for replacement enrollment, but was constrained and not included in the transaction price at quarter-end.
- ARIA cases, including a small number of serious events, occurred in the AL002 Phase 2 Alzheimer’s trial. Alector stopped dosing and enrollment of APOE e4/e4 participants and implemented earlier MRI monitoring; serious events were also reported in some non-homozygous participants.
- Principal risks include clinical and regulatory uncertainty, trial enrollment and safety, reliance on GSK and AbbVie and third-party manufacturers, continuing losses and financing needs, competition, inflation, and potential disruption to access to bank deposits. The filing states that deposits at Silicon Valley Bank were immaterial; approximately $11.4 million exceeded FDIC insurance limits overall.
- The filing reports no litigation considered likely by management to have a material adverse effect. Disclosure controls were deemed effective at a reasonable assurance level, with no material quarterly change in internal control over financial reporting.
Most important facts for investors to verify
- Whether the stated cash runway through 2025 remains supported by updated spending plans, clinical costs, and collaboration receipts.
- Actual progress, enrollment, safety updates, and data timing for INFRONT-3 and INVOKE-2, including the implications of ARIA monitoring and events.
- Regulatory feedback on INFRONT-3 trial design and whether it changes the data-readout or potential filing timeline.
- Recognition of collaboration revenue and any future milestone payments, particularly the constrained AbbVie enrollment milestone.
- Execution and final costs of the workforce reduction, alongside the effect of prioritization on pipeline programs and operating expenses.
- Liquidity and investment-portfolio exposure, including uninsured bank balances and interest-rate sensitivity.